低全球变暖潜力推进剂HFA-152a不会诱导支气管收缩或损害粘膜细胞清除
Michela Salvadori1, Dave Singh2, Kusum Mathews1
1Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Pulmonary pharmacology & therapeutics
|April 7, 2025
概括
在计量剂量吸入器中用碳-134a (HFA-134a) 取代碳-152a (HFA-152a),不太可能导致支气管收缩或影响粘膜干净 (MCC). 这种开关对于喘患者和健康的志愿者来说似乎是安全的.
科学领域:
- 制药科学 制药科学
- 呼吸系统医学 呼吸系统医学
- 环境科学 环境科学
背景情况:
- 在计量剂量吸入器中逐步减少高全球变暖潜力的推进剂,如HFA-134a,需要替代品.
- 碳-152a (HFA-152a) 是一种潜在的低全球变暖潜力替代推进剂.
- 在采用新推进剂之前,安全评估,包括支气管收缩和粘膜清除 (MCC),至关重要.
研究的目的:
- 在患有喘的成年人中,比较HFA-152a与HFA-134a的支气管收缩潜力.
- 评估与HFA-134a相比HFA-152a对健康志愿者的粘膜干净度 (MCC) 的影响.
- 评估HFA-152a作为计量剂量吸入器中替代推进剂的安全概况.
主要方法:
- 支气管收缩研究:喘患者的单剂量,随机,双盲,受控,交叉试验 (N=25). 主要终点:剂后15分钟FEV1的相对变化.
- 粘膜细胞清除 (MCC) 研究:在健康志愿者中进行多剂量 (8天),随机,开放标签,受控,交叉试验 (N=20). 主要终点:在2小时和4小时内保持颗粒的百分比.
- 这两项研究都比较了HFA-152a和HFA-134a,评估了治疗出现的不良事件.
主要成果:
- 支气管收缩研究:HFA-152a证明与HFA-134a相当,FEV1的95% CI差异在-10%至+10%的范围内.
- 粘膜干净度 (MCC) 研究:在HFA-152a和HFA-134a之间在2小时和4小时的颗粒保留中没有发现显著差异.
- 副作用的程度为轻度至中度,在两项研究中都没有报告严重事件;相似比例的参与者经历了轻度不良事件.
结论:
- 这些发现表明,在计量剂量吸入器中用HFA-134a替换HFA-152a不太可能在喘患者中诱导支气管收缩.
- 在健康的志愿者中,HFA-152a似乎不会损害肺粘膜干净度 (MCC).
- 切换到HFA-152a作为推进剂并没有与重大安全问题有关.
相关概念视频
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
239
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
239
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
261
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
261
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
246
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
246
01:19Antiasthma Drugs: Leukotriene Modifiers
253
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
253
01:20Asthma: Pathogenesis and Management
374
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
374
01:24Antiasthma Drugs: Methylxanthines
209
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
209